Description

Oxaliplatin Amaxa Concentrate for Infusions 5 mg/ml. 20 ml. №1

Ingredients:

Each ml contains 5 mg of oxaliplatin. Other ingredients include lactose monohydrate, water for injections, and hydrochloric acid for pH adjustment.

Dosage:

The dosage of Oxaliplatin Amaxa concentrate is individualized based on the patient’s body surface area and overall health condition. It is administered intravenously over a specific period as directed by a healthcare professional.

Indications:

Oxaliplatin Amaxa concentrate is indicated for the treatment of colorectal cancer. It is used in combination with other chemotherapy medications to help slow or stop cancer cell growth.

Contraindications:

Do not use Oxaliplatin Amaxa concentrate if you are allergic to oxaliplatin or any other ingredients in the product. It is important to inform your healthcare provider about any allergies or medical conditions before starting treatment.

Directions:

Oxaliplatin Amaxa concentrate should only be administered by a healthcare professional experienced in chemotherapy treatments. The infusion should be given slowly into a vein to minimize the risk of side effects.

Scientific Evidence:

Studies have shown that Oxaliplatin Amaxa concentrate, in combination with other chemotherapy agents, is effective in the treatment of advanced colorectal cancer. Research published in the Journal of Clinical Oncology demonstrated the efficacy of oxaliplatin-based regimens in improving survival rates and quality of life in patients with colorectal cancer.

Additional Information:

It is important to monitor for potential side effects such as peripheral neuropathy, nausea, and vomiting during treatment with Oxaliplatin Amaxa concentrate. Regular blood tests and medical check-ups are necessary to assess the response to treatment and manage any adverse reactions effectively.

Oxaliplatin Amaxa concentrate for infusions is a vital component in the treatment of colorectal cancer. It works by interfering with the DNA synthesis of cancer cells, ultimately leading to their destruction. This pharmacological action helps in slowing down the progression of the disease and improving patient outcomes.

Clinical trials have shown that Oxaliplatin Amaxa concentrate, when used in combination with fluorouracil and leucovorin, significantly improves overall survival rates in patients with advanced colorectal cancer compared to traditional chemotherapy regimens. The drug’s effectiveness, along with its manageable side effect profile, makes it a preferred choice in the oncology setting.